Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody–positive donors

Matthew S. Chang, Sonja K. Olsen, Elsa M. Pichardo, Scott Heese, Jessica B. Stiles, Rita Abdelmessih, Elizabeth C. Verna, James V. Guarrera, Jean C. Emond, Robert S. Brown – 16 March 2012 – Lamivudine has been shown to prevent de novo hepatitis B virus (HBV) infections in liver transplantation (LT) patients receiving hepatitis B core antibody–positive (HBcAb+) grafts, but it may produce long‐term resistance. Adefovir dipivoxil (ADV) might be effective in preventing de novo hepatitis and resistance.

Immediate intraportal transplantation of human bone marrow mesenchymal stem cells prevents death from fulminant hepatic failure in pigs

Jun Li, Liyuan Zhang, Jiaojiao Xin, Longyan Jiang, Jun Li, Ting Zhang, Linfeng Jin, Jianzhou Li, Pengcheng Zhou, Shaorui Hao, Hongcui Cao, Lanjuan Li – 16 March 2012 – The effectiveness of human bone marrow mesenchymal stem cell (hBMSC) transplantation to treat acute and chronic liver injury has been demonstrated in animal models and in a few nonrandomized clinical trials. However, no studies have investigated hBMSC transplantation in the treatment of fulminant hepatic failure (FHF), especially in large animal (pig) models.

Hemodynamics‐compliant reconstruction of the right hepatic vein for adult living donor liver transplantation with a right liver graft

Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Gi‐Won Song, Ki‐Hun Kim, Dong‐Hwan Jung, Gil‐Chun Park, Kyu‐Bo Sung, Gi‐Young Ko, Kyoung Won Kim, Byungchul Cho, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Chun‐Soo Park, Yo‐Han Park, Hyeong‐Woo Park, Hyo‐Jun Lee, Sung‐Gyu Lee – 16 March 2012 – Secure reconstruction of the right hepatic vein (RHV) is essential for the successful implantation of a right liver graft during living donor liver transplantation (LDLT).

Human mesenchymal stem cells are recruited to injured liver in a β1‐integrin and CD44 dependent manner

Victoria Aldridge, Abhilok Garg, Nicholas Davies, David C. Bartlett, Janine Youster, Heather Beard, Dean P. Kavanagh, Neena Kalia, Jon Frampton, Patricia F. Lalor, Philip N. Newsome – 15 March 2012 – Human bone marrow mesenchymal stem cells (hMSCs) have shown benefit in clinical trials of patients with liver disease. Efficient delivery of cells to target organs is critical to improving their effectiveness. This requires an understanding of the mechanisms governing cellular engraftment into the liver.

Subscribe to